Pivot Pharmaceuticals Inc., a biopharmaceutical company in the cannabis field, signed an Option Agreement last June with IP Med from Oceanside, New York, to acquire an exclusive worldwide license for Trivair Nasal and Pulmonary Breath-Propelled Drug Delivery Systems. Pivot wants it for the delivery of their Ready-To-Infuse-Cannabis (RTIC) cannabinoid products.
The Option is for 6 months, expiring at end of November. In this period, Pivot should have determined compatibility with its RTIC powder formulations. If successful, Pivot will license the TriVair device.
The TriVair patented devices deliver pre-loaded precise unit doses and eliminate the risk of microbial contamination. They won the Frost and Sullivan 2009 European Drug Delivery Product Differentiation Innovation of the Year Award, being easy-to-use, discreet and disposable.
Clinical studies showed they deliver powder throughout the nasal cavity, are effective in retaining medication without pharyngeal penetration, and showed a high degree of patient acceptability.
The TriVair Nasal device uses the body's breath to propel a medication into the nasal cavity to targeted sites, bypassing the Blood Brain Barrier, providing the potential to better treat central nervous system diseases such as migraines, epilepsy, insomnia, and post-operative pain (often treated with opioids.)
The TriVair™ Pulmonary device enables specific dosing to the pulmonary airways, targeting the lungs. This can be relevant in the treatment of respiratory diseases and infections.
Pivot will combine its patented RTIC cannabis powder technology with the TriVair delivery system to provide a rapid onset effect for patients and consumers in markets where regulations permit.
Pivot's chief medical officer, Dr. Wolfgang Renz commented last June "Upon the completion of our compatibility testing, Pivot will have the world's first nasal and pulmonary powdered cannabis device for quick onset and use in the medical field. This combination product may be well suited for managing such indications as sleep disorder, migraine, late-stage cancer pain, and address opioid withdrawal."
Since the 6 month license is about to expire, we look forward to hearing the results of the trial period from Pivot.
Source Pivot press release